Literature DB >> 12923397

Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project.

Carl J Ostgren1, Ulf Lindblad, Olle Melander, Arne Melander, Leif Groop, Lennart Råstam.   

Abstract

OBJECTIVE: This study explored whether the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) is associated with blood pressure in subjects with type 2 diabetes.
DESIGN: A community-based, cross-sectional observation study.
SETTING: Primary care. PATIENTS: One hundred and ninety-two men and 192 women with type 2 diabetes who consecutively underwent annual follow-up. MAIN OUTCOME MEASURE: The PPARgammaPro12Ala genotype was determined by polymerase chain reaction-based techniques. Associations between genotype and blood pressure were analysed by linear regression and expressed as differences in blood pressure (delta) with 95% confidence interval (CI).
RESULTS: The mean systolic blood pressure and the diastolic blood pressure were 160 mmHg (standard deviation = 22.8) and 84 mmHg (standard deviation = 9.6), respectively. Subjects with Pro/Ala (24%) or Ala/Ala (2%) had lower diastolic blood pressure (delta = 2.8; 95% CI, 0.6-5.0) when adjusted for age and gender compared with Pro/Pro subjects (74%). This association was restricted to men (delta = 4.4; 95% CI, 1.3-7.4), who also had a borderline significant difference in systolic blood pressure (delta = 6.9; 95% CI, -0.8 to 13.8). In men the difference in diastolic blood pressure remained after adjustment for age, body mass index, serum triglycerides, serum insulin and haemoglobin A(1c) (delta = 4.6; 95% CI, 1.1-8.1). A subanalysis of normotensive men (n = 100) confirmed the difference associated with the Pro12Ala polymorphism in diastolic blood pressure (delta = 5.2; 95% CI, 0.6-10.0).
CONCLUSIONS: The common Pro12Ala polymorphism in PPARgamma is associated with lower diastolic blood pressure in male subjects with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923397     DOI: 10.1097/01.hjh.0000084734.53355.0d

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  21 in total

1.  Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes.

Authors:  Hulya Yilmaz-Aydogan; Ozlem Kurnaz; Ozlem Kurt; Basak Akadam-Teker; Ozlem Kucukhuseyin; Atike Tekeli; Turgay Isbir
Journal:  Mol Cell Biochem       Date:  2011-07-21       Impact factor: 3.396

2.  The Pro12Ala and C-681G variants of the PPARG locus are associated with opposing growth phenotypes in young schoolchildren.

Authors:  J E Cecil; B Fischer; A S F Doney; M Hetherington; P Watt; W Wrieden; C Bolton-Smith; C N A Palmer
Journal:  Diabetologia       Date:  2005-07-09       Impact factor: 10.122

3.  Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension.

Authors:  W Yang; J Wang; W Ye; X Li
Journal:  Herz       Date:  2017-09-18       Impact factor: 1.443

4.  The PPARγ2 P12A polymorphism is not associated with all-cause mortality in patients with type 2 diabetes mellitus.

Authors:  Antonio Pacilli; Sabrina Prudente; Massimiliano Copetti; Andrea Fontana; Luana Mercuri; Simonetta Bacci; Antonella Marucci; Federica Alberico; Raffaella Viti; Antonio Palena; Olga Lamacchia; Mauro Cignarelli; Salvatore De Cosmo; Vincenzo Trischitta
Journal:  Endocrine       Date:  2016-03-08       Impact factor: 3.633

5.  Associations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.

Authors:  Hassan Rooki; Monir-sadat Haerian; Pedram Azimzadeh; Reza Mirhafez; Mahmoud Ebrahimi; Gordon Ferns; Majid Ghayour-Mobarhan; Mohammad-Reza Zali
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

6.  Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease.

Authors:  Jean Dallongeville; Carlos Iribarren; Jean Ferrières; Liisa Lyon; Alun Evans; Alan S Go; Dominique Arveiler; Stephen P Fortmann; Pierre Ducimetière; Mark A Hlatky; Philippe Amouyel; Audrey Southwick; Thomas Quertermous; Aline Meirhaeghe
Journal:  PPAR Res       Date:  2009-12-01       Impact factor: 4.964

7.  Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes.

Authors:  A S F Doney; B Fischer; J E Cecil; K Boylan; F E McGuigan; S H Ralston; A D Morris; C N A Palmer
Journal:  Diabetologia       Date:  2004-01-17       Impact factor: 10.122

Review 8.  The role of obesity in the pathogenesis of hypertension.

Authors:  Yolanda E Bogaert; Stuart Linas
Journal:  Nat Clin Pract Nephrol       Date:  2008-12-23

Review 9.  Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.

Authors:  Curt D Sigmund
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

10.  Several lipid-related gene polymorphisms interact with overweight/obesity to modulate blood pressure levels.

Authors:  Rui-Xing Yin; Dong-Feng Wu; Lynn Htet Htet Aung; Ting-Ting Yan; Xiao-Li Cao; Xing-Jiang Long; Lin Miao; Wan-Ying Liu; Lin Zhang; Meng Li
Journal:  Int J Mol Sci       Date:  2012-09-24       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.